Facing the challenges of bringing medtech to Germany
The NUB reimbursement pathway has been effective in bringing high-cost innovative medical technologies to the German market, but there are challenges. In...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
CRA’s global expert team supports MedTech clients in developing both product-specific and portfolio/corporate strategies. We rely on our deep understanding of the market environment, extensive prior experience in the MedTech space, and a multidisciplinary approach. Our clients have asked CRA to support them with:
CRA has deep expertise in creating commercial and PMA strategies along the MedTech product lifecycle. We can help you understand, demonstrate, and maximize value.
Price/access/uptake benchmarking and assessments
The NUB reimbursement pathway has been effective in bringing high-cost innovative medical technologies to the German market, but there are challenges. In...
Healthcare systems have had to adapt to evolving challenges in recent years, and in response, the pharmaceutical and biotechnology sectors have implemented...